Talabostat

Drug Profile

Talabostat

Alternative Names: PT-100; ValboroPro

Latest Information Update: 07 May 2015

Price : $50

At a glance

  • Originator Tufts University School of Medicine
  • Developer DARA BioSciences; Point Therapeutics
  • Class Antineoplastics; Boronic acids; Dipeptides; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Chronic lymphocytic leukaemia; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Discontinued Neutropenia

Most Recent Events

  • 12 Feb 2008 Point Therapeutics has been acquired and merged into DARA Biosciences
  • 02 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections
  • 23 May 2007 Suspended - Phase-III for Non-small cell lung cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top